- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03264716
Transarterial Chemoembolization by Hepasphere Microspheres for the Treatment of Unresectable Colorectal Liver Metastasis
A Prospective Open-label Study of Transarterial Chemoembolization by Hepasphere Microspheres for the Treatment of Unresectable Colorectal Liver Metastasis
Colorectal cancer is the third most frequently diagnosed cancer and the third leading cause of cancer related deaths in Taiwan. Of the 10,248 new colorectal patients diagnosed each year approximately 60% will develop liver metastasis during the course of their disease. In approximately 30% of these patients who develop liver metastasis the metastatic disease will remain confined to the liver.
For the 70-75% of colorectal patients with colorectal liver metastasis not suitable for hepatic resection or similarly ablative therapy with curative intent, systemic chemotherapy is the standard initial management. However, after a patient has failed first- line and in some cases second-line chemotherapy, response rates fall to as low as 12% (Chen HX 2006). Transarterial chemoembolization (TACE) with microsphere is an alternative treatment because normal liver tissue receives most of its blood supply from the portal vein, while colorectal liver metastases derive most of their flow from the hepatic artery. Several clinical trials have explored the feasibility and the efficacy of TACE with microsphere as a treatment for patients with colorectal liver metastasis. HepaSphere represents a novel drug delivery system for chemoembolization, which can add two benefits to embolization therapy. First, by ionically binding the doxorubicin throughout the microspheres, more drug can be delivered into the tumor, with less escape into peripheral circulation. Second, conformability to the architecture of the vessel lumen, providing more contact surface area with the embolic material and the vessel intima, leading to a more complete occlusion. However, there are limited experiences in using HepaSphere TACE for colorectal liver metastasis in Taiwan. In this pilot study, we will evaluate the initiate safety and efficacy of Hepasphere microspheres loaded with a chemotherapeutic agent doxorubicin for the treatment of patients who have failed first-line and second-line systemic chemotherapy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, non-comparative study aimed to evaluate the safety profiles and efficacy of patients with unresectable colorectal liver metastases treated by selective TACE (transarterial chemoembolization) using HepaSphere load with doxorubicin. Total of 15 patients will be planned to recruit.
The study procedures will consist of a screening period in which patient eligibility will be determined. Patients meeting the study entry criteria will receive one HepaSphere treatments. Computed tomography (CT) will be done 4 weeks after treatment to determine tumor response.
Hepatic progression free survival will be followed from the date of first study HepaSphere procedure until a date of target liver tumor progression is obtained or the patient is lost to follow-up. Treatments for liver metastases after the study HepaSphere treatments are complete will be documented during the survival period to the extent possible.
The investigators will evaluate subjects' previous treatments and response, and determine to use doxorubicin for subjects. 100 mg doxorubicin will be loaded onto the HepaSphere Microspheres (through ionic bonding when the spheres are exposed to doxorubicin solubilized in non-ionic contrast medium) and delivered via microcatheter. No ethiodized oil is used with the microspheres. The occlusion endpoint will be stasis to the second or third branches. If stasis has not been reached when the target dosage of doxorubicin has been delivered, additional bland embolic agent will be used to achieve a consistent endpoint. Other concurrent chemotherapy, such as Xeloda, 5-fluorouracil but not limited, can be used in combination with HepaSphere Tx.
The study will evaluate safety throughout the protocol specified treatment phase of the investigation by assessing adverse events, as well as changes from baseline in laboratory values, findings on physical examination including vital signs and Eastern Cooperative Oncology Group (ECOG) performance status. Concomitant medication usage will also be assessed.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan
- National Taiwan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must meet all of the following inclusion criteria in order to be entered into the study:
- Liver dominant metastatic colorectal cancer
- Metastatic colorectal patients who have failed first-line and second-line systemic chemotherapy.
- ECOG 0 to 1 or a Karnofsky Performance score of 80-100%;
- Age 20 years or older
- Patient has signed informed consent
Exclusion Criteria:
- If patients meet any of the following criteria they may not be entered into the study:
- History of severe allergy or intolerance to any contrast media not controlled with premedication
- Severe peripheral vascular disease that would preclude catheterization
- Significant extra-hepatic disease, generally in excess of 50% of the overall whole body tumor bulk outside the liver, or any tumor burden that represented an imminent threat to the patient's life
- Greater than 75% hepatic parenchymal involvement. Previous treatment with any form of transarterial embolization for liver tumors
f. Female patients who are pregnant, breastfeeding, or premenopausal and not using an effective method of contraceptive g. Any contraindication to arteriography or hepatic embolization
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: HepaSphere TACE (transarterial chemoembolization)
Using HepaSphere TACE (transarterial chemoembolization) for colorectal liver metastasis.
TACE using HepaSphere load with doxorubicin.
|
100 mg doxorubicin will be loaded onto the HepaSphere Microspheres and delivered via microcatheter.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hepatic Progression free survival
Time Frame: up to one year
|
To define all participants from the day of the first HepaSphere Tx until the date that hepatic progression or death is first reported, whichever comes first.
|
up to one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
An overall tumor response classification
Time Frame: up to one year
|
The tumor response will be assessed using modified Response Evaluation Criteria In Solid Tumors (mRECIST) criteria to evaluate tumor necrosis, and includes assessment of viable tumor, which is defined as uptake of contrast agent in the arterial phase of computed tomography (CT).
|
up to one year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kai-Wen Huang, MD. PhD., National Taiwan University Hospital
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201701124DIPB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unresectable Colorectal Liver Metastasis
-
Azienda Ospedaliera di PadovaIstituto Oncologico Veneto IRCCSRecruitingColorectal Adenocarcinoma | Colorectal Liver Metastases | Unresectable Malignant NeoplasmItaly
-
David BartlettSanofi; The Pittsburgh FoundationCompleted
-
Weill Medical College of Cornell UniversityRecruitingUnresectable Liver-limited Colorectal MetastasesUnited States
-
Fudan UniversityCompletedUnresectable Liver Metastasis of Colorectal CancerChina
-
Samsung Medical CenterCompletedNeoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver MetastasisColorectal Cancer | Unresectable Liver MetastasisKorea, Republic of
-
Amsterdam UMC, location VUmcAngiodynamics, Inc.Not yet recruitingColorectal Cancer | Liver Metastases | Liver Metastasis Colon Cancer | Unresectable Solid Tumor
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingUnresectable Colorectal Liver MetastasesFrance
-
Zhongda HospitalRecruitingYttrium-90 Carbon Microspheres in Patients With Unresectable Colorectal Liver Metastases (NRT-uCRLM)Unresectable Colorectal Liver MetastasesChina
-
Sirtex MedicalRecruitingUnresectable Hepatocellular Carcinoma (HCC) | Liver Metastases From Colorectal Cancer (mCRC)Spain, United Kingdom, France
-
Fudan UniversityUnknownColorectal Cancer Liver MetastasisChina
Clinical Trials on HepaSphere TACE (transarterial chemoembolization)
-
Seoul National University HospitalWithdrawnHepatocellular CarcinomaKorea, Republic of
-
Peking University Cancer Hospital & InstituteNot yet recruitingHCC | Regorafenib | Transarterial Chemoembolization | Hepatic Arterial Infusion Chemotherapy
-
Guangdong Provincial People's HospitalCompletedHepatocellular Carcinoma | Circulating Tumor Cell;China
-
Stanford UniversityTerminatedCarcinoma, Hepatocellular | Hepatobiliary Neoplasm | Liver CarcinomaUnited States
-
Shanghai Zhongshan HospitalNot yet recruiting
-
Second Affiliated Hospital of Guangzhou Medical...RecruitingHepatocellular Carcinoma Non-resectableChina
-
Tongji HospitalNot yet recruitingHepatocellular CarcinomaChina
-
Loma Linda UniversityCompletedCarcinoma, HepatocellularUnited States
-
Fudan UniversityUnknownHepatocellular CarcinomaChina
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | Stage I Adult Primary Liver Cancer | Stage II Adult Primary Liver Cancer | Stage IIIA Adult Primary Liver Cancer